Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for BioAI-global
- ·The full record, as it builds
Funding rounds
No funding rounds for BioAI-global are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioAI-global
Developer and provider of AI-assisted drug discovery technologies designed for drug development in various disease areas. The company provides advanced technologies and services, offering customized models and workflows to enable pharmaceutical companies with flexible drug discovery solutions.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Founded
- 2021
- Website
- bioai-global.com/
- Ownership
- Privately Held (backing)
BioAI-global doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioAI-global shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioAI-global in its N-PORT filings yet. We sweep new filings monthly.